Christopher E Brightling

List of Publications by Year
in descending order

274 papers	28,471 citations	82 h-index	160 g-index
		5574	5988
280 all docs	280 docs citations	280 times ranked	19851 citing authors

#	Article	IF	Citations
1	Cluster Analysis and Clinical Asthma Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 218-224.	5.6	1,727
2	Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. New England Journal of Medicine, 2009, 360, 973-984.	27.0	1,672
3	Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet, The, 2002, 360, 1715-1721.	13.7	1,598
4	Mast-Cell Infiltration of Airway Smooth Muscle in Asthma. New England Journal of Medicine, 2002, 346, 1699-1705.	27.0	1,147
5	Acute Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 662-671.	5.6	847
6	Evidence of a Role of Tumor Necrosis Factor Î± in Refractory Asthma. New England Journal of Medicine, 2006, 354, 697-708.	27.0	783
7	Diagnosis and Management of Cough Executive Summary. Chest, 2006, 129, 1S-23S.	0.8	677
8	Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, The, 2000, 356, 1480-1485.	13.7	514
9	Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 48-55.	5.6	499
10	Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. New England Journal of Medicine, 2021, 384, 1800-1809.	27.0	435
11	Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine,the, 2016, 4, 549-556.	10.7	433
12	Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nature Genetics, 2018, 50, 42-53.	21.4	426
13	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 1275-1287.	10.7	394
14	Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 2020, 55, 1900588.	6.7	380
15	Targeting TNF-Î±: A novel therapeutic approach for asthma. Journal of Allergy and Clinical Immunology, 2008, 121, 5-10.	2.9	332
16	Oxidative stressâ€“induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2015, 136, 769-780.	2.9	332
17	Expression of the T Helper 17-Associated Cytokines IL-17A and IL-17F in Asthma and COPD. Chest, 2010, 138, 1140-1147.	0.8	331
18	Lung microbiome dynamics in COPD exacerbations. European Respiratory Journal, 2016, 47, 1082-1092.	6.7	330

#	Article	IF	Citations
19	Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2015, 3, 692-701.	10.7	318
20	Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax, 2005, 60, 193-198.	5.6	306
21	CCR7 Expression and Memory T Cell Diversity in Humans. Journal of Immunology, 2001, 166, 877-884.	0.8	304
22	The CXCL10/CXCR3 Axis Mediates Human Lung Mast Cell Migration to Asthmatic Airway Smooth Muscle. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1103-1108.	5.6	264
23	The relationship between clinical outcomes and medication adherence in difficult-to-control asthma: Table 1. Thorax, 2012, 67, 751-753.	5.6	259
24	Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nature Genetics, 2017, 49, 416-425.	21.4	257
25	Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respiratory Medicine,the, 2014, 2, 891-901.	10.7	248
26	Increased sputum and bronchial biopsy IL-13 expression in severe asthma. Journal of Allergy and Clinical Immunology, 2008, 121, 685-691.	2.9	243
27	Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Therapeutic Advances in Chronic Disease, 2016, 7, 34-51.	2.5	230
28	Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respiratory Medicine,the, 2019, 7, 402-416.	10.7	225
29	IgE Sensitization toAspergillus fumigatusIs Associated with Reduced Lung Function in Asthma. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1362-1368.	5.6	222
30	Fevipiprant, a prostaglandin D 2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respiratory Medicine,the, 2016, 4, 699-707.	10.7	220
31	Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. European Respiratory Journal, 2022, 59, 2102730.	6.7	218
32	TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. Journal of Allergy and Clinical Immunology, 2002, 110, 899-905.	2.9	207
33	Antiinflammatory Effects of the Phosphodiesterase-4 Inhibitor Cilomilast (Ariflo) in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 976-982.	5.6	207
34	Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nature Communications, 2015, 6, 8327.	12.8	207
35	Association Between Neutrophilic Airway Inflammation and Airflow Limitation in Adults With Asthma. Chest, 2007, 132, 1871-1875.	0.8	204
36	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 17-35.	5.6	196

#	Article	IF	Citations
37	Qualitative Analysis of High-Resolution CT Scans in Severe Asthma. Chest, 2009, 136, 1521-1528.	0.8	190
38	Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. Lancet Respiratory Medicine,the, 2019, 7, 20-34.	10.7	183
39	Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Medicine, 2011, 3, 43.	8.2	181
40	Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.	27.0	180
41	Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respiratory Medicine,the, 2018, 6, 511-525.	10.7	175
42	Induced Sputum Inflammatory Mediator Concentrations in Chronic Cough. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 15-19.	5.6	173
43	A Comparison of the Validity of Different Diagnostic Tests in Adults With Asthma. Chest, 2002, 121, 1051-1057.	0.8	169
44	Expression of Chemokine Receptors by Lung T Cells from Normal and Asthmatic Subjects. Journal of Immunology, 2001, 166, 2842-2848.	0.8	163
45	Airway inflammation in COPD: progress to precision medicine. European Respiratory Journal, 2019, 54, 1900651.	6.7	163
46	Ciliary dysfunction and ultrastructural abnormalities are features of severe asthma. Journal of Allergy and Clinical Immunology, 2010, 126, 722-729.e2.	2.9	156
47	Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. Journal of Allergy and Clinical Immunology, 2004, 114, 1106-1109.	2.9	151
48	Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: AÂ12-month follow-up analysis. Journal of Allergy and Clinical Immunology, 2014, 133, 921-923.	2.9	150
49	An Empiric Integrative Approach to the Management of Cough. Chest, 2006, 129, 222S-231S.	0.8	149
50	Clinical, Radiologic, and Induced Sputum Features of Chronic Obstructive Pulmonary Disease in Nonsmokers. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1078-1083.	5.6	148
51	Procalcitonin and C-Reactive Protein in Hospitalized Adult Patients With Community-Acquired Pneumonia or Exacerbation of Asthma or COPD. Chest, 2011, 139, 1410-1418.	0.8	145
52	Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. European Respiratory Journal, 2014, 44, 789-791.	6.7	141
53	Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2021, 9, 1299-1312.	10.7	139
54	Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis. Chest, 2006, 129, 116S-121S.	0.8	134

#	Article	IF	Citations
55	Airway Smooth Muscle and Mast Cellâ€“derived CC Chemokine Ligand 19 Mediate Airway Smooth Muscle Migration in Asthma. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1179-1188.	5.6	134
56	<scp>IL</scp>â€33 drives airway hyperâ€responsiveness through <scp>IL</scp>â€13â€mediated mast cell: airway smooth muscle crosstalk. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 556-567.	5.7	134
57	Socio-demographic heterogeneity in the prevalence of COVID-19 during lockdown is associated with ethnicity and household size: Results from an observational cohort study. EClinicalMedicine, 2020, 25, 100466.	7.1	129
58	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
59	Eosinophilic airway inflammation in COPD. International Journal of COPD, 2006, 1, 39-47.	2.3	128
60	Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. Journal of Allergy and Clinical Immunology, 2013, 131, 1008-1016.	2.9	125
61	Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. Chest, 2016, 150, 320-328.	0.8	125
62	Integrin Î±vÎ²5-Mediated TGF-Î² Activation by Airway Smooth Muscle Cells in Asthma. Journal of Immunology, 2011, 187, 6094-6107.	0.8	124
63	Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. Journal of Allergy and Clinical Immunology, 2018, 141, 2027-2036.e12.	2.9	124
64	Fibrocyte localization to the airway smooth muscle is a feature of asthma. Journal of Allergy and Clinical Immunology, 2009, 123, 376-384.	2.9	120
65	Clinical Applications of Induced Sputum. Chest, 2006, 129, 1344-1348.	0.8	118
66	Pathogenesis of asthma: implications for precision medicine. Clinical Science, 2017, 131, 1723-1735.	4.3	118
67	Biological clustering supports both â€œDutchâ€•and â€œBritishâ€•hypotheses of asthma and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2015, 135, 63-72.e10.	2.9	111
68	Aspergillus fumigatus during stable state and exacerbations of COPD. European Respiratory Journal, 2014, 43, 64-71.	6.7	110
69	Quantitative computed tomographyâ€“derived clusters: Redefining airway remodeling in asthmatic patients. Journal of Allergy and Clinical Immunology, 2014, 133, 729-738.e18.	2.9	108
70	Inflammatory Endotypeâ€“associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1488-1502.	5.6	107
71	Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respiratory Medicine,the, 2018, 6, 499-510.	10.7	104
72	Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study. Thorax, 2018, 73, 331-338.	5.6	101

#	Article	IF	Citations
73	Human Airway Smooth Muscle Promotes Human Lung Mast Cell Survival, Proliferation, and Constitutive Activation: Cooperative Roles for CADM1, Stem Cell Factor, and IL-6. Journal of Immunology, 2008, 181, 2772-2780.	0.8	100
74	Lung damage and airway remodelling in severe asthma. Clinical and Experimental Allergy, 2012, 42, 638-649.	2.9	100
75	The Role of CT Scanning in Multidimensional Phenotyping of COPD. Chest, 2011, 140, 634-642.	0.8	96
76	Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. Medical Mycology, 2012, 50, 433-438.	0.7	94
77	Blood and sputum eosinophils in COPD; relationship with bacterial load. Respiratory Research, 2017, 18, 88.	3.6	94
78	Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability. PLoS ONE, 2014, 9, e102987.	2.5	94
79	Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. Thorax, 2010, 65, 775-781.	5.6	93
80	Composite type-2 biomarker strategy versus a symptomâ€“risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 57-68.	10.7	88
81	OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma. Chest, 2012, 141, 494-499.	0.8	86
82	Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. Journal of Leukocyte Biology, 2005, 77, 759-766.	3.3	84
83	Clinical utility of fractional exhaled nitric oxide in severe asthma management. European Respiratory Journal, 2020, 55, 1901633.	6.7	83
84	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 735-750.	5.7	83
85	Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: AÂsingle-center study. Journal of Allergy and Clinical Immunology, 2016, 137, 1413-1422.e12.	2.9	78
86	Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. Journal of Allergy and Clinical Immunology, 2017, 139, 1167-1175.e2.	2.9	78
87	Cooperative molecular and cellular networks regulate Tollâ€like receptorâ€dependent inflammatory responses. FASEB Journal, 2006, 20, 2153-2155.	0.5	76
88	Eosinophil protein in airway macrophages: AÂnovel biomarker of eosinophilic inflammation in patients with asthma. Journal of Allergy and Clinical Immunology, 2010, 126, 61-69.e3.	2.9	76
89	Effectiveness of voriconazole in the treatment of Aspergillus fumigatusâ€“associated asthma (EVITA3) Tj ETQq1 1 0.784314 rgBT /Ov	2.9	74
90	Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations. Chest, 2015, 147, 46-55.	0.8	74

#	Article	IF	Citations
91	Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology, 2015, 20, 667-670.	2.3	70
92	Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease Macrophages. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 845-855.	5.6	70
93	Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and) Tj ETQq1 1 0.784314 rgBT /Overlo	10.7	70
94	Interleukinâ€13: prospects for new treatments. Clinical and Experimental Allergy, 2010, 40, 42-49.	2.9	68
95	Asthma Therapy and Its Effect on Airway Remodelling. Drugs, 2014, 74, 1345-1369.	10.9	66
96	Human Airway Smooth Muscle Cells from Asthmatic Individuals Have CXCL8 Hypersecretion Due to Increased NF-Î²B p65, C/EBPÎ², and RNA Polymerase II Binding to the CXCL8 Promoter. Journal of Immunology, 2009, 183, 4682-4692.	0.8	65
97	COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulmonary Medicine, 2014, 14, 112.	2.0	62
98	Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 660-671.	5.6	62
99	Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. International Journal of COPD, 2015, 10, 1075.	2.3	61
100	Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. Lancet Microbe, The, 2021, 2, e300-e310.	7.3	60
101	Origins of increased airway smooth muscle mass in asthma. BMC Medicine, 2013, 11, 145.	5.5	59
102	<scp>CCL</scp>2 release by airway smooth muscle is increased in asthma and promotes fibrocyte migration. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1189-1197.	5.7	59
103	Mast Cell-Airway Smooth Muscle Crosstalk. Chest, 2012, 142, 76-85.	0.8	58
104	DP ₂ antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment. Science Translational Medicine, 2019, 11, .	12.4	57
105	Idiopathic chronic cough and organ-specific autoimmune diseases: a caseâ€“control study. Respiratory Medicine, 2004, 98, 242-246.	2.9	56
106	HMGB1 is upregulated in the airways in asthma and potentiates airway smooth muscle contraction via TLR4. Journal of Allergy and Clinical Immunology, 2017, 140, 584-587.e8.	2.9	55
107	Biomarkers Predicting Response to Corticosteroid Therapy in Asthma. Treatments in Respiratory Medicine, 2005, 4, 309-316.	1.4	53
108	Adenosine closes the K+ channel KCa3.1 in human lung mast cells and inhibits their migrationvia the adenosine A2A receptor. European Journal of Immunology, 2007, 37, 1653-1662.	2.9	53

#	Article	IF	Citations
109	Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 739-750.	5.6	53
110	Neutrophil elastase as a biomarker for bacterial infection in COPD. Respiratory Research, 2019, 20, 170.	3.6	53
111	Abnormal Histone Methylation Is Responsible for Increased Vascular Endothelial Growth Factor 165a Secretion from Airway Smooth Muscle Cells in Asthma. Journal of Immunology, 2012, 189, 819-831.	0.8	52
112	CXCL8 histone H3 acetylation is dysfunctional in airway smooth muscle in asthma: regulation by BET. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L962-L972.	2.9	51
113	The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respiratory Medicine,the, 2021, 9, 1174-1184.	10.7	49
114	Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD. PLoS ONE, 2016, 11, e0163139.	2.5	49
115	Eosinophils as diagnostic tools in chronic lung disease. Expert Review of Respiratory Medicine, 2013, 7, 33-42.	2.5	47
116	Pivotal Advance: Expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors. Journal of Leukocyte Biology, 2009, 86, 479-489.	3.3	46
117	Phenotyping the heterogeneity of chronic obstructive pulmonary disease. Clinical Science, 2013, 124, 371-387.	4.3	46
118	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
119	D prostanoid receptor 2 (chemoattractant receptorâ€“homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects onÂbronchial epithelial cells. Journal of Allergy and Clinical Immunology, 2015, 135, 395-406.e7.	2.9	45
120	The sputum microbiome is distinct between COPD and health, independent of smoking history. Respiratory Research, 2020, 21, 183.	3.6	45
121	Development and Analysis of Patient-Based Complete Conducting Airways Models. PLoS ONE, 2015, 10, e0144105.	2.5	45
122	Bronchoalveolar lavage invariant natural killer T cells are not increased in asthma. Journal of Allergy and Clinical Immunology, 2007, 119, 1274-1276.	2.9	44
123	Computational modeling of the obstructive lung diseases asthma and COPD. Journal of Translational Medicine, 2014, 12, S5.	4.4	44
124	Asthmatic airway smooth muscle CXCL10 production: mitogen-activated protein kinase JNK involvement. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 302, L1118-L1127.	2.9	43
125	NADPH Oxidase-4 Overexpression IsÂAssociated With Epithelial Ciliary Dysfunction in Neutrophilic Asthma. Chest, 2016, 149, 1445-1459.	0.8	43
126	Multi-omic meta-analysis identifies functional signatures of airway microbiome in chronic obstructive pulmonary disease. ISME Journal, 2020, 14, 2748-2765.	9.8	43

#	Article	IF	Citations
127	uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium. Thorax, 2012, 67, 477-487.	5.6	42
128	Computed tomography scans in severe asthma. Current Opinion in Pulmonary Medicine, 2012, 18, 42-47.	2.6	42
129	How to Diagnose and Phenotype Asthma. Clinics in Chest Medicine, 2012, 33, 445-457.	2.1	42
130	In vitro, in silico and in vivo study challenges the impact of bronchial thermoplasty on acute airway smooth muscle mass loss. European Respiratory Journal, 2018, 51, 1701680.	6.7	42
131	The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study. Lancet Respiratory Medicine,the, 2022, 10, 661-668.	10.7	41
132	The impact of the prostaglandin D₂ receptor 2 and its downstream effects on the pathophysiology of asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 761-768.	5.7	40
133	Lung clearance index in adults with non-cystic fibrosis bronchiectasis. Respiratory Research, 2014, 15, 59.	3.6	39
134	ERS Clinical Research Collaborations: underpinning research excellence. European Respiratory Journal, 2018, 52, 1801534.	6.7	39
135	Expression and activation of the oxytocin receptor in airway smooth muscle cells: Regulation by TNFÎ± and IL-13. Respiratory Research, 2010, 11, 104.	3.6	38
136	Bacteria and sputum inflammatory cell counts; a COPD cohort analysis. Respiratory Research, 2020, 21, 289.	3.6	38
137	Primary Human Airway Epithelial Cell-Dependent Inhibition of Human Lung Mast Cell Degranulation. PLoS ONE, 2012, 7, e43545.	2.5	37
138	T2 Biologics for Chronic Obstructive Pulmonary Disease. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1405-1416.	3.8	37
139	Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 370-380.	5.7	37
140	Sputum microbiome profiling in COPD: beyond singular pathogen detection. Thorax, 2020, 75, 338-344.	5.6	37
141	A Refined View of Airway Microbiome in Chronic Obstructive Pulmonary Disease at Species and Strain-Levels. Frontiers in Microbiology, 2020, 11, 1758.	3.5	36
142	Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents. Chest, 2020, 158, 68-96.	0.8	36
143	Airway smooth muscle NOX4 is upregulated and modulates ROS generation in COPD. Respiratory Research, 2016, 17, 84.	3.6	35
144	Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 469-477.	10.7	35

#	Article	IF	Citations
145	Increased glutaredoxin-1 and decreased proteinS-glutathionylation in sputum of asthmatics. European Respiratory Journal, 2013, 41, 469-472.	6.7	34
146	Functional CT imaging for identification of the spatial determinants of small-airways disease in adults with asthma. Journal of Allergy and Clinical Immunology, 2019, 144, 83-93.	2.9	34
147	Eosinophilic Bronchitis. Treatments in Respiratory Medicine, 2003, 2, 169-173.	1.2	33
148	Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilusâ€predominant subgroup. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 808-817.	5.7	33
149	Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome. PLoS ONE, 2017, 12, e0180859.	2.5	33
150	Associations in asthma between quantitative computed tomography andÂbronchial biopsy-derived airway remodelling. European Respiratory Journal, 2017, 49, 1601507.	6.7	32
151	New and emerging drug treatments for severe asthma. Clinical and Experimental Allergy, 2018, 48, 241-252.	2.9	32
152	The stability of blood Eosinophils in chronic obstructive pulmonary disease. Respiratory Research, 2020, 21, 15.	3.6	32
153	Cough Due to Asthma, Cough-Variant Asthma and Non-Asthmatic Eosinophilic Bronchitis. Otolaryngologic Clinics of North America, 2010, 43, 123-130.	1.1	31
154	Eosinophils, bronchitis and asthma: Pathogenesis of cough and airflow obstruction. Pulmonary Pharmacology and Therapeutics, 2011, 24, 324-327.	2.6	31
155	Airway impedance entropy and exacerbations in severe asthma. European Respiratory Journal, 2012, 40, 1156-1163.	6.7	31
156	Global Initiative for Asthma Strategy 2021. Respirology, 2022, 27, 14-35.	2.3	31
157	Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. Archivos De Bronconeumologia, 2022, 58, 35-51.	0.8	31
158	An RGS4-Mediated Phenotypic Switch of Bronchial Smooth Muscle Cells Promotes Fixed Airway Obstruction in Asthma. PLoS ONE, 2012, 7, e28504.	2.5	30
159	InÂvivo imaging reveals increased eosinophil uptake in the lungs of obese asthmatic patients. Journal of Allergy and Clinical Immunology, 2018, 142, 1659-1662.e8.	2.9	30
160	Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation andHaemophilusinfection in COPD. European Respiratory Journal, 2021, 58, 2003312.	6.7	30
161	The EvA study: aims and strategy. European Respiratory Journal, 2012, 40, 823-829.	6.7	29
162	Cough and Eosinophilia. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1740-1747.	3.8	29

#	Article	IF	Citations
163	Phenotypic and functional translation of IL33 genetics in asthma. Journal of Allergy and Clinical Immunology, 2021, 147, 144-157.	2.9	29
164	Characterization of acinar airspace involvement in asthmatic patients by using inert gas washout and hyperpolarized 3helium magnetic resonance. Journal of Allergy and Clinical Immunology, 2016, 137, 417-425.	2.9	28
165	The re-emergence of the mast cell as a pivotal cell in asthma pathogenesis. Current Allergy and Asthma Reports, 2005, 5, 130-135.	5.3	27
166	Chemokine Concentrations and Mast Cell Chemotactic Activity in BAL Fluid in Patients With Eosinophilic Bronchitis and Asthma, and in Normal Control Subjects. Chest, 2006, 130, 371-378.	0.8	27
167	Airway pathological heterogeneity in asthma: Visualization of disease microclusters using topological data analysis. Journal of Allergy and Clinical Immunology, 2018, 142, 1457-1468.	2.9	27
168	The utility of the mannitol challenge in the assessment of chronic cough: a pilot study. Cough, 2008, 4, 10.	2.7	26
169	Regional Ventilation Changes in the Lung: Treatment Response Mapping by Using Hyperpolarized Gas MR Imaging as a Quantitative Biomarker. Radiology, 2017, 284, 854-861.	7.3	26
170	A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. Trials, 2018, 19, 5.	1.6	26
171	Phenotypic and functional translation of IL1RL1 locus polymorphisms in lung tissue and asthmatic airway epithelium. JCI Insight, 2020, 5, .	5.0	26
172	Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma. British Journal of Pharmacology, 2016, 173, 1286-1301.	5.4	25
173	Microbiome balance in sputum determined by PCR stratifies COPD exacerbations and shows potential for selective use of antibiotics. PLoS ONE, 2017, 12, e0182833.	2.5	25
174	Cough Due to Asthma and Nonasthmatic Eosinophilic Bronchitis. Lung, 2010, 188, 13-17.	3.3	24
175	A method for quantitative analysis of regional lung ventilation using deformable image registration of CT and hybrid hyperpolarized gas/1H MRI. Physics in Medicine and Biology, 2014, 59, 7267-7277.	3.0	24
176	Biologic Drugs: A New Target Therapy in COPD?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 99-107.	1.6	24
177	Face mask sampling reveals antimicrobial resistance genes in exhaled aerosols from patients with chronic obstructive pulmonary disease and healthy volunteers. BMJ Open Respiratory Research, 2018, 5, e000321.	3.0	24
178	Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study. BMJ Open, 2019, 9, e025486.	1.9	24
179	Unmet needs for the assessment of small airways dysfunction in asthma: introduction to the ATLANTIS study. European Respiratory Journal, 2015, 45, 1534-1538.	6.7	23
180	Fevipiprant in the treatment of asthma. Expert Opinion on Investigational Drugs, 2018, 27, 199-207.	4.1	23

#	Article	IF	Citations
181	Mast cell infiltration of airway smooth muscle in asthma. Respiratory Medicine, 2007, 101, 1045.	2.9	22
182	Regulator of G-Protein Signalingâ€“5 Inhibits Bronchial Smooth Muscle Contraction in Severe Asthma. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 823-832.	2.9	22
183	Exome-wide analysis of rare coding variation identifies novel associations with COPD and airflow limitation inMOCS3,IFIT3andSERPINA12. Thorax, 2016, 71, 501-509.	5.6	22
184	Chronic obstructive pulmonary disease phenotypes, biomarkers, and prognostic indicators. Allergy and Asthma Proceedings, 2016, 37, 432-438.	2.2	21
185	Between-visit variability of small airway obstruction markers in patients with asthma. European Respiratory Journal, 2014, 44, 242-244.	6.7	20
186	Pathophysiological regulation of lung function by the free fatty acid receptor FFA4. Science Translational Medicine, 2020, 12, .	12.4	20
187	Pre-eclampsia is associated with airway hyperresponsiveness. BJOG: an International Journal of Obstetrics and Gynaecology, 2008, 115, 520-522.	2.3	18
188	Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma. Respiratory Research, 2013, 14, 17.	3.6	18
189	Resistome analyses of sputum from COPD and healthy subjects reveals bacterial load-related prevalence of target genes. Thorax, 2020, 75, 8-16.	5.6	18
190	Urgent need for pragmatic trial platforms in severe asthma. Lancet Respiratory Medicine,the, 2018, 6, 581-583.	10.7	15
191	Adapting the Electrospinning Process to Provide Three Unique Environments for a Tri-layered In Vitro Model of the Airway Wall. Journal of Visualized Experiments, 2015, , e52986.	0.3	14
192	Human group 2 innate lymphoid cells do not express the IL-5 receptor. Journal of Allergy and Clinical Immunology, 2017, 140, 1430-1433.e4.	2.9	14
193	Investigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD. International Journal of COPD, 2017, Volume 12, 1199-1205.	2.3	14
194	Sputum Induction in Asthma. Chest, 2006, 129, 503-504.	0.8	13
195	Effect of Antiâ€“IL-13 Treatment on Airway Dimensions in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 118-120.	5.6	13
196	Anti-IL-5 for Severe Asthma. Chest, 2016, 150, 766-768.	0.8	13
197	Modelling the effect of gravity on inert-gas washout outputs. Physiological Reports, 2018, 6, e13709.	1.7	13
198	Factors Associated with Frequent Exacerbations in the UK Severe Asthma Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2691-2701.e1.	3.8	13

#	Article	IF	Citations
199	The effects of nociceptin peptide (N/OFQ)â€“receptor (NOP) system activation in the airways. Peptides, 2013, 39, 36-46.	2.4	12
200	Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. International Journal of COPD, 2014, 9, 179.	2.3	12
201	Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2014, 9, 975.	2.3	12
202	Effects of older age and age of asthma onset on clinical and inflammatory variables in severe refractory asthma. Respiratory Medicine, 2016, 118, 46-52.	2.9	12
203	Sputum Inflammatory Mediators Are Increased inAspergillus fumigatusCulture-Positive Asthmatics. Allergy, Asthma and Immunology Research, 2017, 9, 177.	2.9	12
204	Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab . International Journal of COPD, 2019, Volume 14, 1177-1185.	2.3	12
205	The different phenotypes of COPD. British Medical Bulletin, 2021, 137, 82-97.	6.9	12
206	Use of the ReCIVA device in breath sampling of patients with acute breathlessness: a feasibility study. ERJ Open Research, 2020, 6, 00119-2020.	2.6	12
207	Severe asthma: novel advances in the pathogenesis and therapy. Polish Archives of Internal Medicine, 2014, 124, 247-254.	0.4	12
208	Stressed out - The role of oxidative stress in airway smooth muscle dysfunction in asthma and COPD. Free Radical Biology and Medicine, 2022, 185, 97-119.	2.9	11
209	Research pointers: Peak expiratory flow sequence in acute exacerbations of asthma. BMJ: British Medical Journal, 2001, 322, 1281-1281.	2.3	10
210	Increased ventilation heterogeneity in asthma can be attributed to proximal bronchioles. European Respiratory Journal, 2020, 55, 1901345.	6.7	10
211	ST2 expression and release by the bronchial epithelium is downregulated in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3184-3194.	5.7	10
212	Airways Disease: Phenotyping Heterogeneity Using Measures of Airway Inflammation. Allergy, Asthma and Clinical Immunology, 2007, 3, 60.	2.0	9
213	Immunopathogenesis of Severe Asthma. Current Pharmaceutical Design, 2011, 17, 667-673.	1.9	9
214	Toll-like receptor 9 dependent interferon-Î± release is impaired in severe asthma but is not associated with exacerbation frequency. Immunobiology, 2015, 220, 859-864.	1.9	9
215	Temporal Assessment of Airway Remodeling in Severe Asthma Using Quantitative Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 107-110.	5.6	9
216	Cohort Profile: Extended Cohort for E-health, Environment and DNA (EXCEED). International Journal of Epidemiology, 2019, 48, 678-679j.	1.9	9

#	Article	IF	Citations
217	Mepolizumab does not alter the blood basophil count in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2488-2490.	5.7	9
218	Tensin1 expression and function in chronic obstructive pulmonary disease. Scientific Reports, 2019, 9, 18942.	3.3	9
219	[<scp><scp>Ca²⁺</scp></scp>]_i oscillations in <scp>ASM</scp>: Relationship with persistent airflow obstruction in asthma. Respirology, 2014, 19, 763-766.	2.3	8
220	Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma. Expert Review of Respiratory Medicine, 2016, 10, 607-617.	2.5	8
221	GINA fosters World Asthma Day 2020 to prevent asthma deaths. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L998-L1000.	2.9	8
222	3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD. European Respiratory Journal, 2021, 58, 2102168.	6.7	8
223	Bronchial thermoplasty: what we know, what we don't know, and what we need to know. European Respiratory Journal, 2022, 59, 2102018.	6.7	8
224	No evidence for altered intracellular calcium-handling in airway smooth muscle cells from human subjects with asthma. BMC Pulmonary Medicine, 2015, 15, 12.	2.0	7
225	Comparison of CT ventilation imaging and hyperpolarised gas MRI: effects of breathing manoeuvre. Physics in Medicine and Biology, 2019, 64, 055013.	3.0	7
226	Fibrocyte localisation to the ASM bundle in asthma: bidirectional effects on cell phenotype and behaviour. Clinical and Translational Immunology, 2020, 9, e1205.	3.8	7
227	Feno differentiates epithelial gene expression clusters: Exploratory analysis from the MESOS randomized controlled trial. Journal of Allergy and Clinical Immunology, 2022, 150, 830-840.	2.9	7
228	Is the Eosinophil a Leading Villain in Lung Function Decline?. Chest, 2015, 148, 844-846.	0.8	6
229	Cigarette Smoke and the Induction of Urokinase Plasminogen Activator ReceptorIn Vivo: Selective Contribution of Isoforms to Bronchial Epithelial Phenotype. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 174-183.	2.9	6
230	Novel imaging approaches in adult asthma and their clinical potential. Expert Review of Clinical Immunology, 2015, 11, 1147-1162.	3.0	6
231	Proning reduces ventilation heterogeneity in patients with elevated BMI: implications for COVID-19 pneumonia management?. ERJ Open Research, 2020, 6, 00292-2020.	2.6	6
232	Pathological disease in the lung periphery after acute COVID-19. Lancet Respiratory Medicine,the, 2021, 9, 1089-1090.	10.7	6
233	Association of gut-related metabolites with respiratory symptoms in COVID-19: A proof-of-concept study. Nutrition, 2022, 96, 111585.	2.4	6
234	Imaging advances in asthma. Expert Opinion on Medical Diagnostics, 2011, 5, 453-465.	1.6	5

#	Article	IF	Citations
235	Comment on â€œUnraveling a Clinical Paradox: Why Does Bronchial Thermoplasty Work in Asthma?â€. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 660-661.	2.9	5
236	Guidance production before evidence generation for critical issues: the example of COVID-19. European Respiratory Review, 2020, 29, 200310.	7.1	5
237	Peripheral and proximal lung ventilation in asthma: Short-term variation and response to bronchodilator inhalation. Journal of Allergy and Clinical Immunology, 2021, 147, 2154-2161.e6.	2.9	5
238	A systematic review of the diagnostic accuracy of volatile organic compounds in airway diseases and their relation to markers of type-2 inflammation. ERJ Open Research, 2021, 7, 00030-2021.	2.6	5
239	The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulmonary Pharmacology and Therapeutics, 2021, 68, 102030.	2.6	5
240	Synthetic Response of Stimulated Respiratory Epithelium. Chest, 2013, 143, 1656-1666.	0.8	4
241	Circulating fibrocytes: Will the real fibrocyte please stand up?. Journal of Allergy and Clinical Immunology, 2016, 137, 1625-1626.	2.9	4
242	FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations. Trials, 2016, 17, 499.	1.6	4
243	Clinical trial research in focus: do trials prepare us to deliver precision medicine in those with severe asthma?. Lancet Respiratory Medicine,the, 2017, 5, 92-95.	10.7	4
244	Sputum Moraxella catarrhalis strains exhibit diversity within and between COPD subjects. International Journal of COPD, 2018, Volume 13, 3663-3667.	2.3	4
245	Volatile organic compounds in a headspace sampling system and asthmatics sputum samples. Journal of Breath Research, 2021, 15, 027102.	3.0	4
246	Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST. Health Technology Assessment, 2018, 22, 1-82.	2.8	4
247	Fatty airways: a source of good and bad fats?. European Respiratory Journal, 2019, 54, 1902060.	6.7	3
248	The ERS fellowship portfolio: fostering excellence and diversity. European Respiratory Journal, 2019, 54, 1901503.	6.7	3
249	Expanding the spectrum of European Respiratory Society official scientific documents: short documents complement clinical practice guidelines, statements and technical standards. European Respiratory Journal, 2020, 55, 2001030.	6.7	3
250	Interleukinâ€18, ILâ€18 binding protein and ILâ€18 receptor expression in asthma: a hypothesis showing ILâ€18 promotes epithelial cell differentiation. Clinical and Translational Immunology, 2021, 10, e1301.	3.8	3
251	High serum G-CSF characterises neutrophilic COPD exacerbations associated with dysbiosis. ERJ Open Research, 2021, 7, 00836-2020.	2.6	3
252	Eosinophils in Asthma and Airway Hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 131-133.	5.6	3

#	Article	IF	Citations
253	Bronchiectasis, the Latest Eosinophilic Airway Disease: What About the Microbiome?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 860-862.	5.6	3
254	Clinical Applications of Induced Sputum. Chest, 2006, 130, 1626-1627.	0.8	2
255	Pharmacological treatment of bacterial infections of the respiratory tract. Anaesthesia and Intensive Care Medicine, 2011, 12, 522-525.	0.2	2
256	Pharmacological treatment of bacterial infections of the respiratory tract. Anaesthesia and Intensive Care Medicine, 2015, 16, 79-82.	0.2	2
257	Pharmacological treatment of bacterial infections of the respiratory tract. Anaesthesia and Intensive Care Medicine, 2018, 19, 72-75.	0.2	2
258	Visual vs Automated Assessment of Emphysema: Response. Chest, 2011, 140, 1385.	0.8	1
259	Destination Airway: Tracking Granulocytes in Asthma. EBioMedicine, 2014, 1, 105-106.	6.1	1
260	Spread the Word About CHEST in 2019. Chest, 2019, 155, 1-4.	0.8	1
261	High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controls. Scientific Reports, 2019, 9, 20158.	3.3	1
262	Asthma exacerbations during pregnancy: A need for precision medicine. Respirology, 2020, 25, 670-671.	2.3	1
263	Letter from the <scp>UK</scp>. Respirology, 2020, 25, 1323-1324.	2.3	1
264	Airways Disease: Phenotyping Heterogeneity Using Measures of Airway Inflammation. Allergy, Asthma and Clinical Immunology, 2007, 03, 60.	2.0	1
265	Procalcitonin vs Clinical and Chest Film Findings to Diagnose Community-Acquired Pneumonia in Patients With Acute Asthma or Acute Exacerbations of Chronic Bronchitis: Response. Chest, 2011, 140, 1668.	0.8	0
266	As strong as an <scp>OX</scp> or as weak as a kitten?. Clinical and Experimental Allergy, 2014, 44, 6-8.	2.9	0
267	Reply. Journal of Allergy and Clinical Immunology, 2014, 133, 1777-1778.	2.9	0
268	Emerging Therapies in Severe Eosinophilic Asthma. Archivos De Bronconeumologia, 2017, 53, 233-234.	0.8	0
269	Emerging Therapies in Severe Eosinophilic Asthma. Archivos De Bronconeumologia, 2017, 53, 233-234.	0.8	0
270	Reply. Journal of Allergy and Clinical Immunology, 2019, 143, 1265-1266.	2.9	0

#	Article	IF	Citations
271	Detection of Cell-Dissociated Non-Typeable Haemophilus influenzae in the Airways of Patients with Chronic Obstructive Pulmonary Disease . International Journal of COPD, 2020, Volume 15, 1357-1365.	2.3	0
272	Cytokine-Specific Therapy in Asthma. , 2014, , 1491-1502.		0
273	Lung Imaging. , 2014, , 1056-1065.		0
274	Imaging severe asthma. , 2019, , 113-131.		0